Microfollinum

Microfollinum – oestrogenic drug.

Form of release and structure

Dosage form – tablets: convex, almost white color, with marking of two points on one party, inodorous (on 10 tablets in blister strip packagings, 1 packaging in a cardboard pack).

Active ingredient: ethinylestradiol, contents in 1 tablet makes 50 mkg.

Additional components: lactoses monohydrate, silicon colloid anhydrous, starch corn, gelatin, magnesium stearate, talc.

Indications to use

• Menopausal syndrome;
• Dysmenorrhea;
• Amenorrhea;
• Oligomenorrhea;
• Metrorrhagias (including in a climacteric);
• Menorrhagias;
• Acne (ordinary eels);
• Termination of a lactation;
• Prostate cancer.

Contraindications

Absolute:

• Idiopathic jaundice or skin itch of pregnant women in the anamnesis;
• Abnormal liver functions;
• State after hepatitis;
• Disturbance of cerebral circulation;
• Thrombophlebitis and thromboembolisms, including in the anamnesis;
• Syndromes of the Rotor and Cudgel Johnson;
• The otosclerosis aggravated in the course of the previous pregnancies;
• Vaginal bleeding of an unknown etiology;
• Endometriosis;
• Existence or suspicion of hormonedependent tumors of an endometria and neck of uterus or mammary glands;
• Disturbance of lipidic exchange;
• Pregnancy;
• Hypersensitivity to drug.

Relative (Microfollinum should be applied with extra care and under constant control of a condition of the patient in connection with the available risk of development of serious complications):

• Cardiovascular disturbances;
• Arterial hypertension;
• Renal failures;
• Bronchial asthma;
• Epilepsy;
• Closed-angle glaucoma;
• Diabetes mellitus.

Route of administration and dosage

Microfollinum should be accepted inside.

The recommended dosing modes:

• Amenorrhea, oligomenorrhea: on 20-100 mkg a day within 20 days then within 5 days intramusculary enter 5000 mkg of progesterone;
• Climacteric frustration at women to 45-year age: on 50 mkg a day;
• Dysmenorrhea: on 10-30 mkg a day in 3 receptions within 20 days, since 4 or 5 day of a menstrual cycle, each 2-3 months;
• Suppression of a lactation: the first 3 days after the delivery – on 20 mkg 3 times a day, the next 3 days – on 10 mkg 3 times a day, the next 3 days – on 10 mkg of 1 times a day;
• Acne: on 30-60 mkg a day; during puberty – on 10-30 mkg a day;
• The breast cancer at women is more senior than 60 years and a prostate cancer at men: on 50-100 mkg 3 times a day in combination with radiation therapy. Prolonged treatment, duration is defined individually. The daily dose is gradually reduced to optimum supporting – 50 mkg.

Side effects

• At patients of both floors: a meteorism, diarrhea, nausea, anorexia, vomiting (generally at use of high doses of drug), intestinal or bilious colic, pancreatitis, hepatitis, obstruction of a gall bladder, peripheral hypostases, a headache (including migraine), dizziness, intolerance of contact lenses;
• At men: gynecomastia, sensitivity and morbidity of chest glands, decrease in a libido;
• At women: an amenorrhea, break bleedings, the intermenstrual smearing vulval allocations, increase in a libido, increase in the sizes, sensitivity and morbidity of mammary glands, a tumor of mammary glands.

The women undergoing treatment concerning a breast cancer, and men with a prostate cancer, besides, can have a thrombosis and a thrombembolia.

Special instructions

Before purpose of Microfollinum the patient has to undergo careful medical examination of chest glands and pelvic bodies, measurement of arterial pressure is also required. At prolonged treatment inspection needs to be repeated periodically (in 6 months, further – at least 1 time a year).

Reception of Microfollinum should be interrupted immediately in the following cases: increase in arterial pressure, a long immobilization (for example, owing to accident), emergence of the first symptoms of a thrombembolia or thrombophlebitis, development of jaundice, an acute disorder of sight, the frequent migrenepodobny headache arising for the first time.

At treatment of patients with cardiovascular diseases, renal failures, arterial hypertension, bronchial asthma and epilepsy it is necessary to consider that drug can cause a delay of water and sodium in an organism.

At patients with closed-angle glaucoma during treatment it is necessary to control intraocular pressure.

At patients with a diabetes mellitus decrease in tolerance to glucose is possible.

Microfollinum can cause breakthrough uterine bleedings therefore in need of prolonged use it is necessary to appoint it cyclically.

Women of childbearing age should consider that in certain conditions ethinylestradiol has contraceptive effect (it is a part of many peroral contraceptive drugs).

Some endocrine researches and hepatic functional tests yield reliable results only 2-4 months later after the end of therapy by Microfollinum.

Medicinal interaction

Ethinylestradiol should be applied with care along with metabolism inductors.

Terms and storage conditions

To store in the place, unavailable to children. To observe temperature condition from 15 to 30 ºС.

Period of validity – 5 years.